A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer

摘要

Sentinel lymph node biopsy(SLNB) is a new surgical technique for local axillary lymph nodes(ALNs) of breast cancer. Large-scale clinical trials have confirmed that undergoing SLNB and ALN dissection(ALND) showed no significant difference for sentinel lymph node(SLN)-negative patients in terms of disease-free survival, overall survival and recurrence-free survival. However, false-negative results are still the main concern of physicians as well as patients who undergo SLNB instead of ALND. The American Society of Breast Surgeons established a task force to suggest acceptable standards for SLNB. In 2000, the task force recommended that the identification rate for SLNB be 85% or higher and the false-negative rate be 5% or lower. This review focuses on clinical factors(tumor volume, multifocal/multi-center cancers, neoadjuvant chemotherapy and skip metastasis), tracer techniques and pathological factors affecting SLNB and explores methods for reducing the false-negative rate.